Borja Pedruzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Borja Pedruzo has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Ana Catalan
University of the Basque Country UPV/EHU
6 shared publications Paolo Fusar-Poli
6 shared publications- Claudia Aymerich
Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom; Biocruces Bizkaia Health Research Institute, OSI Bilbao- Basurto. University of the Basque Country UPV/EHU. Barakaldo. Bizkaia. Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
5 shared publications Claudia Aymerich
4 shared publicationsGonzalo Salazar de Pablo
4 shared publications- Miguel Angel Gonzalez-Torres
Psychiatry Service, Basurto University Hospital, Bilbao, Spain
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 40 (4)
Implementing an early psychosis prevention service in the basque country: Ten lessons from the PREGAP experience
- 18 August 2026
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 40 (4)
Open AccessImplementing an early psychosis prevention service in the basque country: Ten lessons from the PREGAP experience
- Open Access
- 19 July 2026
- Published by Association for Computing Machinery (ACM)
- p. 3374-3380
CT CL : A Cross-Language Benchmark for Matching Patients to Clinical Trials
- 19 July 2026
- Published by Association for Computing Machinery (ACM)
- p. 3374-3380
Open AccessCT CL : A Cross-Language Benchmark for Matching Patients to Clinical Trials
- Open Access
- 30 January 2026
- Published by Elsevier in Spanish Journal of Psychiatry and Mental Health
Childhood maltreatment and social cognition deficits across the psychosis spectrum: Evidence from the PREGAP study
- 30 January 2026
- Published by Elsevier in Spanish Journal of Psychiatry and Mental Health
Open AccessChildhood maltreatment and social cognition deficits across the psychosis spectrum: Evidence from the PREGAP study
- Open Access
- 18 July 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (6) , 766-780
Systematic Review and Meta-Analysis: Neurocognitive Alterations in Offspring of Individuals With Schizophrenia or Bipolar Disorder Compared to Offspring of Unaffected Parents
- 18 July 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (6) , 766-780
Open AccessSystematic Review and Meta-Analysis: Neurocognitive Alterations in Offspring of Individuals With Schizophrenia or Bipolar Disorder Compared to Offspring of Unaffected Parents
- Open Access
- 10 July 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-29
Peripheral inflammation and neurocognitive functioning in early psychosis: Specific associations of TNF-α and IL-6 with social cognition
Background: Cognitive deficits and immune system dysregulation are core features of psychotic disorders. Among inflammatory markers, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) have been linked to both psychosis pathophysiology and related cognitive impairments. Methods: We investigated associations among IL-6, TNF-α, and neurocognitive performance in 107 participants: individuals at clinical high risk for psychosis (CHR-P, n = 35), first-episode psychosis (FEP, n = 39), and healthy controls (HC, n = 33). Assessments included memory, processing speed, executive function, and social cognition. Cytokines were measured from fasting serum samples. Analyses included ANOVA, correlations, and multivariate regressions controlling for age, sex, IQ, group, and symptom severity. Results: TNF-α levels were significantly elevated in FEP compared to CHR-P (p = 0.0251); IL-6 differences were non-significant. FEP showed poorer performance in multiple cognitive domains, especially social cognition. CHR-P individuals exhibited intermediate profiles between FEP and HC in cognition. In adjusted regression models, IL-6 was significantly associated with undermentalization on the MASC task (β = 0.28, p = 0.0337) and showed a trend-level association with slower processing speed (β = 0.98, p = 0.075). TNF-α levels predicted poorer facial emotion recognition (β = −1.37, p = 0.0022). IQ and group were significant covariates in most models. Conclusions: Our findings suggest that peripheral inflammation, particularly IL-6 and TNF-α, may selectively impact social cognitive functioning in early psychosis. Though modest, these associations highlight potential inflammatory contributions to functional impairment and support further investigation of immunological targets in early intervention.
- 10 July 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-29
Open AccessPeripheral inflammation and neurocognitive functioning in early psychosis: Specific associations of TNF-α and IL-6 with social cognition
Background: Cognitive deficits and immune system dysregulation are core features of psychotic disorders. Among inflammatory markers, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) have been linked to both psychosis pathophysiology and related cognitive impairments. Methods: We investigated associations among IL-6, TNF-α, and neurocognitive performance in 107 participants: individuals at clinical high risk for psychosis (CHR-P, n = 35), first-episode psychosis (FEP, n = 39), and healthy controls (HC, n = 33). Assessments included memory, processing speed, executive function, and social cognition. Cytokines were measured from fasting serum samples. Analyses included ANOVA, correlations, and multivariate regressions controlling for age, sex, IQ, group, and symptom severity. Results: TNF-α levels were significantly elevated in FEP compared to CHR-P (p = 0.0251); IL-6 differences were non-significant. FEP showed poorer performance in multiple cognitive domains, especially social cognition. CHR-P individuals exhibited intermediate profiles between FEP and HC in cognition. In adjusted regression models, IL-6 was significantly associated with undermentalization on the MASC task (β = 0.28, p = 0.0337) and showed a trend-level association with slower processing speed (β = 0.98, p = 0.075). TNF-α levels predicted poorer facial emotion recognition (β = −1.37, p = 0.0022). IQ and group were significant covariates in most models. Conclusions: Our findings suggest that peripheral inflammation, particularly IL-6 and TNF-α, may selectively impact social cognitive functioning in early psychosis. Though modest, these associations highlight potential inflammatory contributions to functional impairment and support further investigation of immunological targets in early intervention.
- Open Access
- 21 December 2024
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 34 (6) , 1973
Correction: Longitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review
- 21 December 2024
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 34 (6) , 1973
Open AccessCorrection: Longitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review
- Open Access
- 18 May 2023
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 33 (10) , 3377-3387
Longitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review
Clinical high risk of psychosis (CHR-P) population has become an attractive area of interest in preventing transitions to psychosis. The consequences of developing a psychotic disorder may be worse in cases of early onset. Thus, childhood and adolescence represent a critical developmental window, where opportunities to gain social and adaptive abilities depend on the individuals’ neurocognitive performance. There have been previous syntheses of the evidence regarding neurocognitive functioning in CHR-P individuals and its longitudinal changes. However, there has been less focus on children and adolescents at CHR-P. A multistep literature search was performed from database inception until July 15th, 2022. PRIMSA/MOOSE compliant systematic review and PROSPERO protocol were used to identify studies reporting on longitudinal changes in neurocognitive functioning in children and adolescents (mean age of sample ≤ 18 years) at CHR-P and matched healthy control (HC) group. A systematic review of identified studies was then undertaken. Three articles were included, resulting in a total sample size of 151 CHR-P patients [mean (SD) age, 16.48 (2.41) years; 32.45% female] and 64 HC individuals [mean (SD) age, 16.79 (2.38) years; 42.18% female]. CHR-P individuals had worse outcomes in verbal learning, sustained attention and executive functioning domains compared to HC. Individuals taking antidepressants had better outcomes in verbal learning in contrast with those taking antipsychotics. In children and adolescents, neurocognition may be already impaired before the psychosis onset, and remains stable during the transition to psychosis. Further study should be performed to obtain more robust evidence.
- 18 May 2023
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 33 (10) , 3377-3387
Open AccessLongitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review
Clinical high risk of psychosis (CHR-P) population has become an attractive area of interest in preventing transitions to psychosis. The consequences of developing a psychotic disorder may be worse in cases of early onset. Thus, childhood and adolescence represent a critical developmental window, where opportunities to gain social and adaptive abilities depend on the individuals’ neurocognitive performance. There have been previous syntheses of the evidence regarding neurocognitive functioning in CHR-P individuals and its longitudinal changes. However, there has been less focus on children and adolescents at CHR-P. A multistep literature search was performed from database inception until July 15th, 2022. PRIMSA/MOOSE compliant systematic review and PROSPERO protocol were used to identify studies reporting on longitudinal changes in neurocognitive functioning in children and adolescents (mean age of sample ≤ 18 years) at CHR-P and matched healthy control (HC) group. A systematic review of identified studies was then undertaken. Three articles were included, resulting in a total sample size of 151 CHR-P patients [mean (SD) age, 16.48 (2.41) years; 32.45% female] and 64 HC individuals [mean (SD) age, 16.79 (2.38) years; 42.18% female]. CHR-P individuals had worse outcomes in verbal learning, sustained attention and executive functioning domains compared to HC. Individuals taking antidepressants had better outcomes in verbal learning in contrast with those taking antipsychotics. In children and adolescents, neurocognition may be already impaired before the psychosis onset, and remains stable during the transition to psychosis. Further study should be performed to obtain more robust evidence.
- Top Cited PapersOpen Access
- 21 January 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , e10
COVID-19 pandemic effects on health worker’s mental health: Systematic review and meta-analysis
Background: Healthcare workers (HCWs) exposed to coronavirus 19 (COVID-19) are at high risk of developing mental health concerns across several domains. The aim of this study is to determine the updated, global frequency of these outcomes.Methods: A multistep literature search was performed from database inception until March 1, 2021. PRISMA/MOOSE-compliant systematic review and PROSPERO protocol were used to identify studies reporting on depression, anxiety, acute stress, post-traumatic symptoms, insomnia, and burnout in HCWs exposed to COVID-19. A quantitative meta-analysis with random effects was conducted to analyze the proportion rate of the mental health disorders. Sensitivity analyses were performed to investigate the effect of the different continents and scales. Meta-regression analyses were conducted to examine the effect of gender, age, and work position.Results: 239 articles were included (n = 271,319 HCWs, mean age = 36.08 ± 8.33 (66.99% female). 33% HCWs exposed to COVID-19 reported depressive symptoms (95% confidence intervals [CI] = 28–38%), 42% anxiety features (95% CI = 35–48), 40% acute stress (95% CI = 32–47), 32% post-traumatic symptoms (95% CI = 26–37%), 42% insomnia (95% CI = 36–48), 37% burnout (95% CI = 31–42). Sensitivity analyses did not show statistically significant differences. Meta-regressions found a statistically significant lower prevalence of post-traumatic symptoms in Asia.Conclusions: HCWs exposed to COVID-19 were found to have a significant prevalence of mental health concerns in all domains analyzed. The effects of COVID-19 on HCWs’ mental health could be underestimated and the future consequences dismissed.
- 21 January 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , e10
Top Cited PapersOpen AccessCOVID-19 pandemic effects on health worker’s mental health: Systematic review and meta-analysis
Background: Healthcare workers (HCWs) exposed to coronavirus 19 (COVID-19) are at high risk of developing mental health concerns across several domains. The aim of this study is to determine the updated, global frequency of these outcomes.Methods: A multistep literature search was performed from database inception until March 1, 2021. PRISMA/MOOSE-compliant systematic review and PROSPERO protocol were used to identify studies reporting on depression, anxiety, acute stress, post-traumatic symptoms, insomnia, and burnout in HCWs exposed to COVID-19. A quantitative meta-analysis with random effects was conducted to analyze the proportion rate of the mental health disorders. Sensitivity analyses were performed to investigate the effect of the different continents and scales. Meta-regression analyses were conducted to examine the effect of gender, age, and work position.Results: 239 articles were included (n = 271,319 HCWs, mean age = 36.08 ± 8.33 (66.99% female). 33% HCWs exposed to COVID-19 reported depressive symptoms (95% confidence intervals [CI] = 28–38%), 42% anxiety features (95% CI = 35–48), 40% acute stress (95% CI = 32–47), 32% post-traumatic symptoms (95% CI = 26–37%), 42% insomnia (95% CI = 36–48), 37% burnout (95% CI = 31–42). Sensitivity analyses did not show statistically significant differences. Meta-regressions found a statistically significant lower prevalence of post-traumatic symptoms in Asia.Conclusions: HCWs exposed to COVID-19 were found to have a significant prevalence of mental health concerns in all domains analyzed. The effects of COVID-19 on HCWs’ mental health could be underestimated and the future consequences dismissed.
- Open Access
- 3 November 2021
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 64 (1) , 1-24
Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis
Background: To determine the proportion of patients in symptomatic remission and recovery following a first-episode of psychosis (FEP). Methods: A multistep literature search using the Web of Science database, Cochrane Central Register of Reviews, Ovid/PsychINFO, and trial registries from database inception to November 5, 2020, was performed. Cohort studies and randomized control trials (RCT) investigating the proportion of remission and recovery following a FEP were included. Two independent researchers searched, following PRISMA and MOOSE guidelines and using a PROSPERO protocol. We performed meta-analyses regarding the proportion of remission/recovery (symptomatic plus functional outcomes). Heterogeneity was measured employing Q statistics and I2 test. To identify potential predictors, meta-regression analyses were conducted, as well as qualitative reporting of studies included in a systematic review. Sensitivity analyses were performed regarding different times of follow-up and type of studies. Results: One hundred articles (82 cohorts and 18 RCTs) were included in the meta-analysis. The pooled proportion of symptomatic remission was 54% (95%CI [30, 49–58]) over a mean follow-up period of 43.57 months (SD = 51.82) in 76 studies. After excluding RCT from the sample, the proportion of remission remained similar (55%). The pooled proportion of recovery was 32% (95%CI [27–36]) over a mean follow-up period of 71.85 months (SD = 73.54) in 40 studies. After excluding RCT from the sample, the recovery proportion remained the same. No significant effect of any sociodemographic or clinical predictor was found. Conclusions: Half of the patients are in symptomatic remission around 4 years after the FEP, while about a third show recovery after 5.5 years.
- 3 November 2021
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 64 (1) , 1-24
Open AccessProportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis
Background: To determine the proportion of patients in symptomatic remission and recovery following a first-episode of psychosis (FEP). Methods: A multistep literature search using the Web of Science database, Cochrane Central Register of Reviews, Ovid/PsychINFO, and trial registries from database inception to November 5, 2020, was performed. Cohort studies and randomized control trials (RCT) investigating the proportion of remission and recovery following a FEP were included. Two independent researchers searched, following PRISMA and MOOSE guidelines and using a PROSPERO protocol. We performed meta-analyses regarding the proportion of remission/recovery (symptomatic plus functional outcomes). Heterogeneity was measured employing Q statistics and I2 test. To identify potential predictors, meta-regression analyses were conducted, as well as qualitative reporting of studies included in a systematic review. Sensitivity analyses were performed regarding different times of follow-up and type of studies. Results: One hundred articles (82 cohorts and 18 RCTs) were included in the meta-analysis. The pooled proportion of symptomatic remission was 54% (95%CI [30, 49–58]) over a mean follow-up period of 43.57 months (SD = 51.82) in 76 studies. After excluding RCT from the sample, the proportion of remission remained similar (55%). The pooled proportion of recovery was 32% (95%CI [27–36]) over a mean follow-up period of 71.85 months (SD = 73.54) in 40 studies. After excluding RCT from the sample, the recovery proportion remained the same. No significant effect of any sociodemographic or clinical predictor was found. Conclusions: Half of the patients are in symptomatic remission around 4 years after the FEP, while about a third show recovery after 5.5 years.